Casimersen, sold under the brand name AMONDYS 45, received approval from the U.S. Food and Drug Administration in February 2021 through the agency’s Accelerated Approval pathway. The drug treats a specific subset of patients with Duchenne muscular dystrophy (DMD) whose genetic mutations are amenable to skipping exon 45 of the dystrophin gene. That subset accounts for roughly 8% of the DMD population, making casimersen one of several exon-skipping drugs each tailored to a different genetic slice of the disease. The approval rested not on proof that the drug slows disease progression in a traditional sense, but on a more unusual measure: evidence that treated patients produced more dystrophin protein in their muscles than they had before.
What Casimersen Does at the Molecular Level
DMD is caused by mutations in the gene that codes for dystrophin, a protein that acts like a shock absorber for muscle fibers. Without functional dystrophin, muscle cells are damaged every time they contract, leading to progressive muscle wasting that typically confines boys to wheelchairs by their early teens and shortens life expectancy. The mutations that cause DMD usually knock the gene’s reading frame out of alignment, so the cell cannot produce any usable dystrophin at all.
Casimersen is an antisense oligonucleotide, a short synthetic strand of modified genetic material designed to latch onto a specific stretch of the dystrophin gene’s messenger RNA before it gets translated into protein. By binding to exon 45, casimersen causes the cell’s machinery to skip over that exon during processing. The result is a shorter-than-normal but still partially functional dystrophin protein. Administered intravenously, casimersen essentially converts the severe reading-frame disruption seen in DMD into something closer to the milder condition known as Becker muscular dystrophy, where patients produce a truncated dystrophin that retains some protective function.
The Basis for FDA Approval
Casimersen’s approval was granted under the FDA’s Accelerated Approval Program, which allows drugs for serious conditions to reach the market based on a surrogate endpoint, a lab measure that is reasonably likely to predict clinical benefit rather than direct proof of that benefit. In this case, the surrogate endpoint was an observed increase in dystrophin production in skeletal muscle tissue of treated patients.
The key clinical trial was a multicenter, randomized, double-blind, placebo-controlled phase 1/2 study that enrolled 12 participants aged 7 to 21 years, most of whom had limited ambulation or were nonambulatory. During the first 12 weeks, participants were randomized in a 2:1 ratio to receive weekly casimersen infusions at escalating doses of 4, 10, 20, and 30 mg/kg, or placebo. That dose-titration phase was followed by an open-label extension lasting up to 132 weeks, during which all participants received casimersen. Muscle biopsies taken before and after treatment showed increased dystrophin levels in the casimersen-treated group compared to placebo.
The approval comes with an important caveat. Because it was based on a surrogate marker rather than demonstration of improved motor function or delayed disease progression, the manufacturer is required to conduct confirmatory trials. If those post-marketing studies fail to show clinical benefit, the FDA can withdraw the approval. This same pathway was used for the earlier exon-skipping drug eteplirsen, whose approval in 2016 sparked considerable debate among regulators and clinicians about how much dystrophin increase is enough to matter clinically.
Safety Profile From Clinical Trials
In the phase 1/2 trial, participants received casimersen for an average of about 140 weeks. Every participant, whether on casimersen or placebo, experienced at least one treatment-emergent adverse event, but the vast majority of those events, over 91%, were classified as mild. There were no deaths during the study, no dose reductions required, no abnormalities in laboratory values or vital signs, and no serious adverse events considered related to casimersen.
The most commonly reported side effects were upper respiratory tract infections, cough, fever, headache, and joint pain, none of which were clearly distinguishable from what the placebo group experienced or from what would be expected in a population of children and young adults with DMD. Because the trial was small, rare adverse events could easily go undetected, which is another reason ongoing post-marketing surveillance matters.
One area that clinicians watch carefully with antisense oligonucleotide drugs in general is kidney function. The phosphorodiamidate morpholino oligomer (PMO) chemistry that casimersen uses is considered to have a relatively favorable renal profile compared to some other oligonucleotide chemistries, but routine monitoring of kidney function is still part of the prescribing guidance. Urine protein testing before and during treatment is standard practice.
How Casimersen Fits Among Other DMD Therapies
Casimersen is not the only exon-skipping drug approved for DMD. Eteplirsen (Exondys 51), which targets exon 51 skipping, was the first to reach the market in 2016. Golodirsen (Vyondys 53) followed in 2019, targeting exon 53. Viltolarsen (Viltepso), also targeting exon 53, was approved in 2020. Each of these drugs addresses a different subset of DMD patients based on which exon their particular mutation makes amenable to skipping. Together, these four approved therapies cover a meaningful fraction of the DMD population, though many patients have mutations that do not respond to any currently approved exon-skipping approach.
Direct comparisons between these drugs are difficult. The trials used different patient populations, different endpoints, and different measurement techniques for dystrophin. Eteplirsen, for example, has been associated with a mean increase in dystrophin levels of around 0.81% from baseline in its target population, while casimersen data have shown comparable improvements in the exon 45 population. These numbers are extremely small in absolute terms, a healthy person produces 100% of normal dystrophin, but even tiny amounts of functional protein may offer some structural benefit to muscle cells. Whether these small increases translate into meaningful clinical improvement remains the central unresolved question for the entire class of drugs.
Beyond exon-skipping therapies, the DMD treatment landscape also includes corticosteroids like deflazacort and prednisone, which remain the standard of care for slowing muscle deterioration, and newer approaches like gene therapy. Delandistrogene moxeparvovec (Elevidys), a gene therapy that delivers a shortened dystrophin gene via an adeno-associated virus, received accelerated approval in 2023. It takes a fundamentally different approach from exon skipping by delivering a functional gene copy rather than trying to repair the existing one.
Who Is Eligible for Casimersen
Only patients whose DMD-causing mutation is confirmed as amenable to exon 45 skipping can be prescribed casimersen. Determining eligibility requires precise genetic testing. The standard diagnostic approach uses a technique called multiplex ligation-dependent probe amplification (MLPA), which identifies exactly which exons are deleted or duplicated in the dystrophin gene. MLPA can detect both deletions and duplications in patients and carriers, and it pinpoints the specific exons involved, which is critical for determining which exon-skipping therapy, if any, could help a given patient.
MLPA has some limitations. Small mutations within an exon can occasionally mimic a single-exon deletion on the test, so additional testing using PCR with intronic primers is typically performed to confirm the result. Analysis of the RNA transcript is also used to establish precisely whether a patient’s mutation would respond to exon skipping. For families receiving a DMD diagnosis, genetic counselors often walk through these results in detail, because the specific mutation determines not just prognosis but also which emerging therapies might be available.
Newborn screening programs are beginning to incorporate DMD-specific genetic analysis. Some pilot programs have explored screening specifically for deletions amenable to exon-skipping therapy, with positive results confirmed using MLPA on a fresh blood sample. The rationale is that earlier identification could allow treatment to begin before significant muscle damage has occurred, though whether starting exon-skipping drugs earlier actually leads to better outcomes has not been established in clinical trials.
The Cost and Access Problem
Casimersen carries an annual list price in the range of several hundred thousand dollars per patient, consistent with other exon-skipping therapies for DMD. The financial burden on both families and payers has grown rapidly as more DMD-targeted drugs have reached the market. An analysis of U.S. Medicaid data found that total prescriptions for DMD-targeted therapies increased nearly 30-fold between 2017 and 2022, rising from 643 prescriptions (when only eteplirsen was available) to a peak of 19,855 prescriptions across all four approved drugs. Total Medicaid reimbursement for these therapies grew from about $22 million in 2017 to roughly $641 million in 2022. The average cost per individual prescription did decrease slightly over that period, dropping about 6%, but the explosion in utilization far outpaced any per-unit savings.
Insurance coverage varies. Many private insurers and Medicaid programs cover exon-skipping drugs, but prior authorization requirements are common, and denials are not unusual given the limited clinical evidence base. The manufacturer offers patient assistance programs, and advocacy organizations like Parent Project Muscular Dystrophy help families navigate the access landscape. For families outside the United States, access is more complicated. Casimersen’s approval has been primarily a U.S. story; regulatory bodies in Europe and elsewhere have generally demanded stronger clinical evidence before granting approval to exon-skipping drugs.
Why the Evidence Debate Matters
The approval of casimersen and its sibling drugs sits at the center of an ongoing tension in drug regulation. On one side are patient advocates and families who argue that DMD is a devastating, fatal disease with no cure, and that any drug showing biological activity deserves to be available while more data are collected. On the other side are scientists and some regulators who worry that approving drugs based on tiny increases in a protein biomarker, without evidence that patients actually feel or function better, sets a dangerous precedent and exposes patients to unknown long-term risks while costing the healthcare system hundreds of millions of dollars.
The dystrophin increases observed with casimersen and similar drugs are real but very small in absolute terms. Whether those increases meaningfully slow the relentless progression of DMD or simply represent a measurable but clinically insignificant biochemical change is genuinely uncertain. Confirmatory trials designed to assess functional outcomes like walking ability, respiratory function, and quality of life are ongoing, but results take years in a slowly progressive disease. Until those results arrive, clinicians and families are making treatment decisions in a zone of considerable uncertainty.
Next-Generation Exon-Skipping Research
One of the recognized limitations of current exon-skipping drugs, including casimersen, is that the PMO chemistry they use does not penetrate all tissues equally. Skeletal muscle takes up some of the drug, which is why biopsies show dystrophin increases, but cardiac muscle has proven much harder to reach. This matters because heart failure is a leading cause of death in DMD. Standard PMOs have shown very little effectiveness in cardiac tissue in preclinical studies.
Researchers are working on next-generation delivery strategies to overcome this problem. One promising approach involves attaching cell-penetrating peptides to the morpholino backbone, creating what are called peptide-conjugated PMOs, or PPMOs. In animal models, PPMOs show dramatically improved uptake across tissues, including the heart. Studies in a dog model of DMD demonstrated that PPMOs could achieve exon skipping in cardiac muscle, a result that standard PMOs struggled to replicate. Mouse studies using a peptide called DG9 conjugated to PMOs showed improved dystrophin restoration and muscle function compared to unconjugated PMOs.
PPMOs and related next-generation compounds are still in preclinical and early clinical development. If they succeed, they could address two key weaknesses of current therapies simultaneously: poor cardiac penetration and the overall low efficiency of dystrophin restoration. Some researchers envision multi-exon skipping strategies using PPMOs that could apply to a broader range of DMD mutations than the current one-drug-per-exon model allows. That would be a significant step, because the current approach of developing a separate drug for each skippable exon means that each individual drug serves only a small fraction of the DMD population.
Living With DMD While the Science Evolves
For families currently managing DMD, the approval of casimersen represents one piece of a larger care picture. Corticosteroids remain the backbone of treatment, and their benefits on muscle strength and function are better established than those of exon-skipping drugs. Physical therapy, respiratory support, cardiac monitoring, and orthopedic interventions all play major roles in maintaining quality of life and extending survival. Over the past few decades, improvements in supportive care have already pushed median survival for DMD patients from the late teens into the late twenties and beyond.
Deciding whether to pursue casimersen or another exon-skipping drug is a conversation that typically involves a neuromuscular specialist, a genetic counselor, and the family. The decision weighs the uncertain but possible benefit of modest dystrophin restoration against the practical realities of weekly intravenous infusions, the financial burden, and the fact that these drugs have not yet been proven to change the disease’s clinical course. Some families view the biological plausibility and the surrogate endpoint data as sufficient reason to start treatment, especially if the alternative is doing nothing mutation-specific while waiting for stronger evidence. Others prefer to hold off, particularly if their child is still ambulatory and responding well to corticosteroids and physical therapy.
Clinical registries and natural history studies are actively collecting data on patients receiving exon-skipping therapies in real-world settings. These registries will eventually help clarify whether the small dystrophin increases translate into slower disease progression over years of treatment. In a disease where the timeline of decline is measured in years rather than months, meaningful answers from these observational efforts are still some time away.